Alphamab Oncology

SEHK:9966 Stock Report

Market Cap: HK$3.3b

Alphamab Oncology Management

Management criteria checks 2/4

Alphamab Oncology's CEO is Ting Xu, appointed in Nov 2008, has a tenure of 16.08 years. total yearly compensation is CN¥6.88M, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 33.1% of the company’s shares, worth HK$1.10B. The average tenure of the management team and the board of directors is 5.9 years and 5.1 years respectively.

Key information

Ting Xu

Chief executive officer

CN¥6.9m

Total compensation

CEO salary percentage95.2%
CEO tenure16.1yrs
CEO ownership33.1%
Management average tenure5.9yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar

Nov 14
After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar

Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Sep 30
Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable

Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Jun 20
Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding

Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

May 06
Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up

Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Mar 13
Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking

Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Jan 17
Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price

Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

May 21
Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch

Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Mar 01
Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts

Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Oct 04
Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?

Is Alphamab Oncology (HKG:9966) A Risky Investment?

May 21
Is Alphamab Oncology (HKG:9966) A Risky Investment?

Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

Oct 05
Rock star Growth Puts Alphamab Oncology (HKG:9966) In A Position To Use Debt

CEO Compensation Analysis

How has Ting Xu's remuneration changed compared to Alphamab Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥216m

Mar 31 2024n/an/a

-CN¥213m

Dec 31 2023CN¥7mCN¥7m

-CN¥211m

Sep 30 2023n/an/a

-CN¥214m

Jun 30 2023n/an/a

-CN¥218m

Mar 31 2023n/an/a

-CN¥272m

Dec 31 2022CN¥7mCN¥6m

-CN¥326m

Sep 30 2022n/an/a

-CN¥309m

Jun 30 2022n/an/a

-CN¥292m

Mar 31 2022n/an/a

-CN¥352m

Dec 31 2021CN¥7mCN¥5m

-CN¥412m

Sep 30 2021n/an/a

-CN¥502m

Jun 30 2021n/an/a

-CN¥592m

Mar 31 2021n/an/a

-CN¥510m

Dec 31 2020CN¥5mCN¥4m

-CN¥428m

Sep 30 2020n/an/a

-CN¥652m

Jun 30 2020n/an/a

-CN¥877m

Mar 31 2020n/an/a

-CN¥851m

Dec 31 2019CN¥5mCN¥3m

-CN¥833m

Compensation vs Market: Ting's total compensation ($USD942.24K) is above average for companies of similar size in the Hong Kong market ($USD393.64K).

Compensation vs Earnings: Ting's compensation has increased whilst the company is unprofitable.

CEO

Ting Xu (51 yo)

16.1yrs

Tenure

CN¥6,877,000

Compensation

Dr. Ting Xu, Ph D., serves Chief Executive Officer at Alphamab Oncology since October 1, 2018. He Founded Alphamab Oncology in November 2008.Dr. Xu serves as Executive Director at Alphamab Oncology since...

Leadership Team

NamePositionTenureCompensationOwnership
Ting Xu
Founder16.1yrsCN¥6.88m33.1%
HK$ 1.1b
Yang Liu
VP of Corporate Operations & Executive Director6.2yrsCN¥2.97mno data
Yumin Wan
Vice President of Government Affairs & Public Relations5.9yrsno datano data
Mike Liu
Senior Vice President of Business Development6.6yrsno datano data
Jing Han
Chief Commercial Officer3.1yrsno datano data
Lok Yee Chan
Joint Company Secretary4.4yrsno datano data
Qiulan Cheng
Joint Company Secretaryless than a yearno datano data

5.9yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 9966's management team is seasoned and experienced (5.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ting Xu
Founder6.8yrsCN¥6.88m33.1%
HK$ 1.1b
Yang Liu
VP of Corporate Operations & Executive Director6.2yrsCN¥2.97mno data
Cheng Wei
Independent Non-Executive Director5.1yrsCN¥396.00kno data
Man Cho
Non-Executive Directorless than a yearno data0.11%
HK$ 3.6m
Jason J. Luke
Member of Scientific Advisory Boardno datano datano data
Yiping Yang
Member of Scientific Advisory Boardno datano datano data
Dong Wu
Independent Non-Executive Director5.1yrsCN¥396.00kno data
Lei Zheng
Member of Scientific Advisory Boardno datano datano data
Zihai Li
Chairman of Scientific Advisory Boardno datano datano data
Zijian Guo
Independent Non-Executive Director3.3yrsCN¥378.00kno data

5.1yrs

Average Tenure

55yo

Average Age

Experienced Board: 9966's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:41
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alphamab Oncology is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouCitigroup Inc
null nullCLSA
null nullGuoyuan Securities (HK) Ltd